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of a QA programme and to feed back deviations to 
investigators.  
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Purpose/Objective: Continuous Positive Airway Pressure 
(CPAP) has long been used in patients with obstructive sleep 
apnea to maintain airway patency. There are no reports 
describing CPAP use with radiation therapy. We performed a 
prospective clinical trial to determine if CPAP reduces tumor 
motion, expands lung volume and improves dosimetric 
parameters in patients receiving lung SBRT. 
Materials and Methods: IRB approval was given in December 
2013. Inclusion criteria included adult patients with primary 
or secondary lung tumors referred for SBRT. Following 
informed consent and training, subjects underwent 4D 
simulation twice: without CPAP (free-breathing) and with 
CPAP. Treatment was planned using Eclipse (Varian). The ITV 
was expanded 5mm to create PTV. Volumetric and dosimetric 
parameters with and without CPAP were compared using 
Student's paired two-tailed t-test. CPAP was utilized during 
treatment if judged beneficial. Daily cone beam CT's were 
taken. 
Results: Twelve patients were enrolled, one subject 
withdrew due to mask discomfort, 11 were planned and 10 
were treated to 18 different lesions. Mean dose (Eq2GY): 85 
Gy (range: 32Gy-126Gy), One patient was treated with a 
SBRT boost and received 33Gy (Eq2Gy). CPAP increased mean 
lung volume by 26.4% (CI 95%, 20-32.8, p 
Conclusions: CPAP used during lung SBRT was safe, well 
tolerated, and provided clinical and dosimetric benefit in 
almost all patients. Compared to free breathing, CPAP 
increased total lung volume, decreased ITV and PTV, and 
reduced heart and lung dose. Clinical trials are in progress 
studying additional applications and optimal methods for use 
of this novel technique.  
   
PO-0658   
Quality assurance programme for the isotoxic intensity 
modulated radiotherapy feasibility study 
N. Groom1, Y. Tsang1, M. Hatton2, G. Hanna3, K. Franks4, S. 
Harden5, F. McDonald6, S. Harrow7, C. Faivre-Finn8 
1Mount Vernon Hospital, Radiotherapy Physics Department, 
Manchester, United Kingdom  
2Weston Park Hospital Sheffield, Clinical Oncology, Sheffield, 
United Kingdom 
3Northern Ireland Cancer Centre, Clinical Oncology, Belfast, 
United Kingdom  
4St James' University Hospital, Clinical Oncology, Leeds, 
United Kingdom  
5Addenbrookes Hospital, Clinical Oncology, Cambridge, 
United Kingdom  
6The Royal Marsden NHS Foundation Trust, Clinical Oncology, 
Sutton, United Kingdom  
7Beatson West of Scotland Cancer Centre, Clinical Oncology, 
Glasgow, United Kingdom  
8The Christie NHS Foundation Trust, Radiation Related 
Research, Manchester, United Kingdom  
 
Purpose/Objective: Isotoxic IMRT is a multicentre feasibility 
study recruiting patients with stage III non small cell lung 
cancer, not suitable for concurrent chemo-radiotherapy. 
Patients recruited will be treated with individualised doses of 
radiation based on pre-specified normal tissue doses. 
Radiotherapy will be delivered twice-daily over a maximum 
period of 4.5 weeks using IMRT and the radiation dose will be 
increased until one or more of the OAR tolerance or the 
maximum dose of 79.2Gy is reached.  
As part of the quality assurance programme (QA) a 
comparison of the conformity of organ at risk (OAR) outlining 
and planning technique has been undertaken. 
Materials and Methods: Centres were asked to complete an 
outlining benchmark case (assessing OAR outlining) and a 
planning benchmark case (assessing treatment planning 
technique).  
The outlining results presented are from 5 centres (A to E) as 
the outlines from the sixth centre (F) were used as the gold 
standard (GS) outlines for the exercise. 
DICE similarity coefficient (DSC) was defined as 
(2 * UNION of Vol_GS and Vol_centre) / (Vol_GS + 
Vol_centre).  
DSC values range from 0 to 1, with1 denoting complete 
conformity to the gold standard and levels above 0.6 
considered good for this case. 
Results: Outlining benchmark case - Figure 1 shows DSC for 
centres A to E for the OAR outlining. 
Planning benchmark case- 4 out of the 6 centres were able to 
achieve the maximum dose/number of fractions. The most 
common limitation to dose escalation was dose to the 1cc 




Conclusions: Results show good conformity of OAR outlining 
from centres A-E compared to gold standard outlines, except 
for brachial plexus. PTV coverage for all centres was 
compliant with the limits set by the trial protocol. 
Pre-trial QA is an essential part of the trial QA process as it 
will reduce the risk of deviation from protocol.  
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Purpose/Objective: In our previous work[1], a multivariable 
normal tissue complication probability (NTCP) model for 
acute esophageal toxicity (AET) grade ≥2 after (chemo-
)radiotherapy (CRT) for non-small cell lung cancer (NSCLC) 
was developed for patients treated with intensity-modulated 
radiation therapy (IMRT), based on clinical risk factors and 3D 
dose-volume histogram (DVH) parameters of the esophagus. 
In this NTCP analysis, the esophagus was considered a ‘solid’ 
organ, whereas it seems more realistic to consider it as a 
‘hollow’ organ, and establish an NTCP model based on 2D 
dose-surface parameters. We investigated the hypothesis 
that incorporating 2D dose-surface data with and without 
spatial information improves the predictive power of our 
NTCP model based on 3D dose-volume data. 
Materials and Methods: For 149 advanced-stage NSCLC 
patients treated with IMRT, dose-surface histograms (DSHs) 
and polar dose-surface maps (DSMs) (Figure 1) were 
generated with an in-house developed MATLAB-based 
software tool.  
 
Parameters extracted from the DSHs include: a) conventional 
DSH without spatial information, b) contiguous DSH (cDSH) 
representing the largest connected surface area (CSA) 
receiving at least a certain dose, and c) combined cDSH 
representing all CSAs receiving at least a certain dose, scaled 
with decreasing weights for increasing distance to largest 
CSA. Parameters extracted for DSMs include: d) 
circumferential (transverse plane) dose-length histogram 
(cDLH) and e) longitudinal (cranio-caudal direction) dose-
length histogram (lDLH). Following our previous work[1], new 
multivariable NTCP models were developed with the MATLAB-
based DREES tool, consisting of 4 prognostic factors: 
concurrent chemoradiotherapy, gender, tumor stage and the 
most predictive DSH or DSM parameter from method a) to e) 
as identified by logistic regression analysis. Predictive 
performance of these NTCP models was assessed by the area 
under the curve (AUC) of the receiver operator characteristic 
(ROC) graph and by comparison with the established NTCP 
model. 
Results: Univariate logistic regression analysis identified the 
following parameters to show a highly significant correlation 
with AET: mean esophageal dose (MED) for a) DSH, b) cDSH, 
c) combined cDSH, and the maximum length of the 
esophageal surface receiving a contiguous dose ≥60 Gy (L60Gy) 
for d) cDLH and e) lDLH. Substituting MED for these 
parameters in the established NTCP model[1] resulted in AUCs 
of a) 0.83, b) 0.83, c) 0.82, d) 0.81, and e) 0.80, as compared 
to 0.84 found in the previous work based on 3D DVH data. 
Conclusions: Incorporating 2D dose-surface data with and 
without spatial information did not improve the predictive 
performance of the multivariable NTCP model based on 3D 
dose-volume data. 
[1] R. Wijsman, F. Dankers, E. Troost, A. Hoffmann, J. 
Bussink. Multivariable predictive modeling of esophageal 
toxicity after IMRT for advanced stage NSCLC. Submitted 
ESTRO 2015.  
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Purpose/Objective: CONVERT is an international randomised 
phase III trial, which recruited good performance status 
patients with limited-stage small cell lung cancer from April 
2008 until November 2013. 547 patients were recruited in 
total. Patients were randomised to receive 45Gy in 30 
fractions twice-daily (control arm) or 66Gy in 33 fractions 
once-daily (trial arm) given concurrently with 
cisplatin/etoposide. The primary endpoint was overall 
survival. 
In recent years the advancement of radiotherapy techniques 
has been particularly beneficial for lung radiotherapy with 
the aims of improving local control and reducing normal 
tissue complications. For example, imaging techniques such 
as 4DCT and PET CT have improved the accuracy of tumour 
and organ at risk delineation. Use of type B treatment 
planning algorithms is of particular importance in a low 
electron density region such as lung tissue. 
Here, we present some of the findings from a survey which 
was sent out to clinicians who had randomised patients into 
the CONVERT trial to establish what techniques were being 
used to plan and treat trial patients towards the end of the 
trial.  
Materials and Methods: A survey was sent out to 63 centres 
based in Belgium, Canada, France, Netherlands, Slovenia, 
Spain, Ireland and the UK who participated in the CONVERT 
Trial between April 2008 and November 2013. The survey was 
completed using the online survey tool – Survey Monkey. For 
the purpose of this study we focus on pre-treatment imaging, 
treatment planning and delivery technique and on treatment 
imaging techniques used by centres towards the end of the 
trial, and some country by country analysis.  
